MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives

Journal of Immunology Research
Domenico AquinoValeria Cuccarini

Abstract

Pseudophenomena, that is, imaging alterations due to therapy rather than tumor evolution, have an important impact on the management of glioma patients and the results of clinical trials. RANO (response assessment in neurooncology) criteria, including conventional MRI (cMRI), addressed the issues of pseudoprogression after radiotherapy and concomitant chemotherapy and pseudoresponse during antiangiogenic therapy of glioblastomas (GBM) and other gliomas. The development of cancer immunotherapy forced the identification of further relevant response criteria, summarized by the iRANO working group in 2015. In spite of this, the unequivocal definition of glioma progression by cMRI remains difficult particularly in the setting of immunotherapy approaches provided by checkpoint inhibitors and dendritic cells. Advanced MRI (aMRI) may in principle address this unmet clinical need. Here, we discuss the potential contribution of different aMRI techniques and their indications and pitfalls in relation to biological and imaging features of glioma and immune system interactions.

References

Sep 1, 1992·AJR. American Journal of Roentgenology·D Le BihanN Patronas
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D S WilliamsA P Koretsky
Feb 1, 1991·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·P S Tofts, A G Kermode
Jan 1, 1994·Biophysical Journal·P J BasserD LeBihan
Nov 1, 1996·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·L OstergaardB R Rosen
Feb 25, 1999·Journal of Magnetic Resonance Imaging : JMRI·T SugaharaM Takahashi
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jan 18, 2006·Annual Review of Medicine·Judah Folkman
Mar 22, 2006·European Journal of Nuclear Medicine and Molecular Imaging·Gabriele PöpperlKlaus Tatsch
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alba A BrandesMario Ermani
May 3, 2008·The Lancet Oncology·Dieta BrandsmaMartin J van den Bent
Oct 22, 2008·Expert Review of Neurotherapeutics·Marc-André WeberBram Stieltjes
Nov 26, 2008·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Weiying DaiDavid C Alsop
Nov 29, 2008·AJNR. American Journal of Neuroradiology·E M HaackeY-C N Cheng
Apr 21, 2009·Nature Medicine·Craig J GalbánBrian D Ross
Sep 4, 2009·European Journal of Radiology·Chuanting LiLebin Wu
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christina TsienBrian D Ross
Oct 1, 2010·Journal of Magnetic Resonance Imaging : JMRI·Naomi MoritaElias R Melhem
Jan 1, 2007·Journal of Medical Physics·Jan HrabeDavid N Guilfoyle
Mar 12, 2011·AJNR. American Journal of Neuroradiology·L C Hygino da CruzA G Sorensen

❮ Previous
Next ❯

Citations

Apr 27, 2018·The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica·Whitney B Pope, Garth Brandal
Nov 10, 2018·The British Journal of Radiology·Derek R JohnsonTimothy J Kaufmann
Aug 28, 2019·Journal of Clinical Medicine·Jamie D CostabileD Ryan Ormond
Dec 28, 2018·NPJ Precision Oncology·Erin R BonnerJavad Nazarian
Mar 7, 2020·Frontiers in Cell and Developmental Biology·Abbye E McEwenChristina M Lockwood
Dec 7, 2019·Nature Reviews. Cancer·John H SampsonDavid M Ashley
Jan 27, 2021·Current Oncology Reports·Abigail L MendeJennifer L Clarke
Dec 31, 2020·Cancers·Stefaan W Van GoolWilfried Stuecker
Dec 10, 2020·Journal of medical and biological engineering·Patricia ClementEsther A H Warnert
Nov 30, 2020·Drug Discovery Today·Rebecca KassubekHeiko G Niessen
May 1, 2021·International Journal of Molecular Sciences·Sanjeev ChawlaHarish Poptani
May 1, 2021·Cancers·Laura EscuderoJoan Seoane
Apr 27, 2021·Frontiers in Pharmacology·Zaizhong WangJianhua Zhang
Jul 3, 2021·Diagnostics·Jun NakataHaruo Sugiyama

❮ Previous
Next ❯

Methods Mentioned

BETA
total resection
transgenic

Software Mentioned

ASL
iRANO

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.